4-(4,5-dihydro-1H-pyrazol-5-yl)pyridinee | 1015170-78-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(4,5-dihydro-1H-pyrazol-5-yl)pyridinee
• 英文别名: 5-(pyridin-4-yl)-4,5-dihydro-1H-pyrazole；4-(3,4-dihydro-2H-pyrazol-3-yl)-pyridine；4-(4,5-dihydro-1H-pyrazol-5-yl)pyridine
• CAS: 1015170-78-1
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: KFRDWFSAUYARBD-UHFFFAOYSA-N

物化性质

• 沸点：
  311.3±35.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4,5-dihydro-1H-pyrazol-5-yl)pyridinee 在 吡啶 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 生成 N-(3-chlorophenyl)sulfonyl-N'-ethyl-3-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide
  参考文献：
  名称：

  N′-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT₆R) Antagonists with Unique Structural Features

  摘要：

  The 5-HT6 receptor (5-HT6R) has been in the spotlight for several years regarding CNS-related diseases. We set out to discover novel, neutral 5-HT6R antagonists to improve off-target selectivity compared to basic amine-containing scaffolds dominating the field. High-throughput screening identified the N'-(sulfonyl)pyrazoline-1-carboxamidine scaffold as a promising neutral core for starting hit-to-lead. Medicinal chemistry, molecular modeling, small molecule NMR and X-ray crystallography were subsequently applied to optimize the leads into antagonists (compounds 1-49) displaying high 5-HT6R affinity with optimal off-target selectivity. Unique structural features include a pseudoaromatic system and an internal hydrogen bond freezing the bioactive conformation. While physicochemical properties and CNS availability were generally favorable, significant efforts had to be made to improve metabolic stability. The optimized structure 42 is an extremely selective, hERG-free, high-affinity 5-HT6R antagonist showing good human in vitro metabolic stability. Rat pharrnacokinetic data were sufficiently good to enable further in vivo profiling.

  DOI：

  10.1021/jm200466r
• 作为产物：
  描述：

  (E)-3-(pyridin-4-yl)acrylaldehyde 在 肼 作用下， 以 乙醚 为溶剂， 生成 4-(4,5-dihydro-1H-pyrazol-5-yl)pyridinee
  参考文献：
  名称：

  WO2008/34863

  摘要：

  公开号：

文献信息

• N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES
  申请人：VORONOIBIO INC.

  公开号：US20210284647A1

  公开（公告）日：2021-09-16

  The N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative exhibits excellent inhibitory activity against at least one kinase selected from the group consisting of ABL1, ABL2, AURKB, BRK, CDK11, CDK8, CDK9, CDKL2, CIT, DDR1, FLT3, HIPK4, HUNK, JAK3, KIT, LOK, LTK, MET, MLK2, MUSK, MYO3A, PAK3, PCTK3, PDGFRA, PDGFRB, RIPK1, TIE1 and ZAK, and thus being useable as a therapeutic agent for kinase-related disease.

  N-(3-(咪唑[1,2-b]吡啶并[3,4-d]嘧啶-3-乙炔基)-4-甲基苯基)-5-苯基-4,5-二氢-1H-吡唑-1-甲酰胺衍生物对ABL1、ABL2、AURKB、BRK、CDK11、CDK8、CDK9、CDKL2、CIT、DDR1、FLT3、HIPK4、HUNK、JAK3、KIT、LOK、LTK、MET、MLK2、MUSK、MYO3A、PAK3、PCTK3、PDGFRA、PDGFRB、RIPK1、TIE1和ZAK中的至少一种激酶具有优异的抑制活性，因此可作为治疗激酶相关疾病的药物。
• Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase
  作者：Philip A. Harris、Nicolas Faucher、Nicolas George、Patrick M. Eidam、Bryan W. King、Gemma V. White、Niall A. Anderson、Deepak Bandyopadhyay、Allison M. Beal、Veronique Beneton、Scott B. Berger、Nino Campobasso、Sebastien Campos、Carol A. Capriotti、Julie A. Cox、Alain Daugan、Frederic Donche、Marie-Hélène Fouchet、Joshua N. Finger、Brad Geddes、Peter J. Gough、Pascal Grondin、Bonnie L. Hoffman、Sandra J. Hoffman、Susan E. Hutchinson、Jae U. Jeong、Emilie Jigorel、Pauline Lamoureux、Lara K. Leister、John D. Lich、Mukesh K. Mahajan、Jamel Meslamani、Julie E. Mosley、Rakesh Nagilla、Pamela M. Nassau、Sze-Ling Ng、Michael T. Ouellette、Kishore K. Pasikanti、Florent Potvain、Michael A. Reilly、Elizabeth J. Rivera、Stéphane Sautet、Michelle C. Schaeffer、Clark A. Sehon、Helen Sun、James H. Thorpe、Rachel D. Totoritis、Paris Ward、Natalie Wellaway、David D. Wisnoski、James M. Woolven、John Bertin、Robert W. Marquis

  DOI：10.1021/acs.jmedchem.9b00318

  日期：2019.5.23

  RIP1 kinase inhibitors starting from a high-throughput screen and the lead-optimization of this series from a lead with minimal rat oral exposure to the identification of dihydropyrazole 77 with good pharmacokinetic profiles in multiple species. Additionally, we identified a potent murine RIP1 kinase inhibitor 76 as a valuable in vivo tool molecule suitable for evaluating the role of RIP1 kinase in chronic

  RIP1激酶调节坏死病和炎症，并可能在促成多种人类疾病（包括炎症和神经疾病）中发挥重要作用。目前，RIP1激酶抑制剂已进入早期临床试验，以评估炎性疾病（如牛皮癣，类风湿性关节炎和溃疡性结肠炎）以及神经系统疾病（如肌萎缩性侧索硬化症和阿尔茨海默氏病）。在本文中，我们从高通量筛选开始，研究了有效和高度选择性的二氢吡唑（DHP）RIP1激酶抑制剂的设计，并从具有最小大鼠口服暴露量的铅中对该系列的铅进行了优化，以鉴定二氢吡唑77在多个物种中具有良好的药代动力学特征。此外，我们确定了一种强效的鼠RIP1激酶抑制剂76作为一种有价值的体内工具分子，适用于评估RIP1激酶在慢性疾病模型中的作用。DHP 76在多发性硬化症和人类视网膜色素变性的小鼠模型中均显示出功效。
• [EN] ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS<br/>[FR] DÉRIVÉS DE CARBOXAMIDINE DE PYRAZOLINE ARYLSULFONYLIQUE FORMANT DES ANTAGONISTES DE 5-HT6
  申请人：SOLVAY PHARM BV

  公开号：WO2009115515A1

  公开（公告）日：2009-09-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5- HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  这项发明涉及芳基磺酰基吡唑啉羧酰胺衍生物作为5-HT6受体拮抗剂，以及用于制备这些化合物的方法和用于它们合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们在向患者施用以达到在帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫性障碍、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、暴食症、暴食症、恐慌发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒除可卡因、乙醇、尼古丁或苯二氮卓类药物滥用、疼痛、与脊柱损伤或头部损伤相关的障碍、脑积水、功能性肠道障碍、肠易激综合征、肥胖和2型糖尿病中的治疗效果方面的应用。这些化合物具有一般公式（1），其中符号的含义如描述中所示。
• SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Van Loevezijn Arnold

  公开号：US20080311179A1

  公开（公告）日：2008-12-18

  This invention concerns compounds of the general formula (1). and derivatives thereof, which are antagonists of 5-HT 6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  本发明涉及通式（1）的化合物及其衍生物，它们是5-HT6受体拮抗剂，其中符号的含义如说明书所示。本发明还涉及制备这些化合物的方法，对于其合成有用的新型中间体，以及这些化合物和组合物的用途，特别是将它们用于向患者施用以达到治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤有关的疾病、脑积水、功能性肠道障碍、肠易激综合征、肥胖症和2型糖尿病等至少一种疾病或症状的治疗效果。
• ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Loevezijn Arnold Van

  公开号：US20110046171A1

  公开（公告）日：2011-02-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及芳基磺酰基吡唑啉羧酰胺衍生物，其作为5-ht6受体拮抗剂，以及用于制备这些化合物的方法和有用于它们的合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们用于给患者治疗帕金森病、亨廷顿病、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚症候群、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓创伤或头部损伤有关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病。这些化合物具有通式（1），其中符号的含义如描述中所给。